This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

AMAG Pharmaceuticals Appoints Steven Caffe, M.D. As Chief Development And Regulatory Officer

Stocks in this article: AMAG

LEXINGTON, Mass., June 24, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the appointment of Steven Caffé, M.D. as senior vice president and chief development and regulatory officer. Dr. Caffé brings 20 years of experience in global biopharmaceuticals development and regulatory approvals to AMAG. He joins AMAG from MedImmune, AstraZeneca's global biologics research and development arm, where he most recently served as senior vice president of global regulatory affairs and patient safety.

"Steve brings a wealth of relevant development and regulatory experience to AMAG, gained through a distinguished 20-year career in pharmaceutical companies ranging from Merck & Co. to MedImmune," said William Heiden, president and chief executive officer of AMAG. "His experience in global product development and life-cycle management strategies and execution will be invaluable to us near-term as we work towards the potential regulatory approval of Feraheme® for the treatment of iron deficiency anemia in a broader patient population, and longer-term as our product portfolio expands through our on-going business development activities. We are pleased to welcome Steve to AMAG."

Dr. Caffé commented, "AMAG is undergoing a significant turnaround, with the continued growth of Feraheme and the addition of MuGard™ forming a solid foundation on which we can build a premier specialty pharmaceutical company. I am energized to join the company at this time and look forward to sharing the journey with the talented team at AMAG."

Dr. Caffé has broad-based industry experience across several therapeutic areas, and in the development of biopharmaceuticals and medical devices. Early in his career, Dr. Caffé served as a medical director for Parke-Davis, before its acquisition by Pfizer, and has since had roles of increasing responsibility at major pharmaceutical companies. Through his experience at Merck & Co., Sanofi, Baxter and most recently MedImmune, Dr. Caffé has assembled and led high-performing teams through many development and regulatory programs, successfully achieving key new product approvals and extending the life cycle of several commercial products. Dr. Caffé received his medical degree from the Faculté de Médecine Saint-Antoine, Université Pierre et Marie Curie (Paris 6), completed his internship and residency, and practiced medicine at the academic hospitals of the Assistance Publique de Paris with a focus on emergency and intensive care.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs